Sign inCreate account

Report workspace tools

NCT05985122ACTIVE_NOT_RECRUITINGanonymous

Towards the Most Accurate Diagnosis and Monitoring of Complement-mediated Rare Kidney Diseases

Sponsor

Source record

Mario Negri Institute for Pharmacological Research

Phase

Source record

NA

Modality

AI-normalized

RNA therapy

Target

AI-normalized

Complement-mediated Rare Kidney Diseases (aHUS and C3G)

Indication / condition

AI-normalized

Hemolytic-Uremic Syndrome

Intervention

Source record

C3NEF assay

Source & freshness

Source record

NCT ID

NCT05985122

Original source

ClinicalTrials.gov

Source last updated

Mar 23, 2026

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05985122

Title

Towards the Most Accurate Diagnosis and Monitoring of Complement-mediated Rare Kidney Diseases

Sponsor

Mario Negri Institute for Pharmacological Research

Status

ACTIVE_NOT_RECRUITING

Phase

NA

Condition raw

Hemolytic-Uremic Syndrome

Condition normalized

Hemolytic-Uremic Syndrome

Modality raw

Hemolytic-Uremic Syndrome

Modality normalized

RNA therapy

Target raw

Complement-mediated Rare Kidney Diseases (aHUS and C3G)

Target normalized

Complement-mediated Rare Kidney Diseases (aHUS and C3G)

Interventions

C3NEF assay

Public preview

Source record

The COMPRare project aims to develop new diagnostic tools for aHUS and C3G, improving patient stratification and treatment monitoring. Funded by the EJP RD program of the EU, it involves a consortium of seven European institutions. The study focuses on identifying biomarkers and standardizing assays to enhance diagnosis and treatment options for these ultra-rare conditions.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Towards the Most Accurate Diagnosis and Monitoring of Complement-mediated Rare Kidney Diseases

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05985122

Status

ACTIVE_NOT_RECRUITING

Phase

NA

Sponsor

Mario Negri Institute for Pharmacological Research

Executive brief

Investment-Ready Snapshot

The COMPRare project aims to develop new diagnostic tools for aHUS and C3G, improving patient stratification and treatment monitoring. Funded by the EJP RD program of the EU, it involves a consortium of seven European institutions. The study focuses on identifying biomarkers and standardizing assays to enhance diagnosis and treatment options for these ultra-rare conditions.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 23, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05985122

Indication

Hemolytic-Uremic Syndrome

Modality

RNA therapy

Target

Complement-mediated Rare Kidney Diseases (aHUS and C3G)

Intervention

C3NEF assay

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.